Latest news

May 09, 2025

Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 31, 2025

Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications

Mar 27, 2025

Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology

X